DE60330888D1 - Verwendung von drospirenon zur behandlung von hypertension - Google Patents

Verwendung von drospirenon zur behandlung von hypertension

Info

Publication number
DE60330888D1
DE60330888D1 DE60330888T DE60330888T DE60330888D1 DE 60330888 D1 DE60330888 D1 DE 60330888D1 DE 60330888 T DE60330888 T DE 60330888T DE 60330888 T DE60330888 T DE 60330888T DE 60330888 D1 DE60330888 D1 DE 60330888D1
Authority
DE
Germany
Prior art keywords
women
drospirenone
hypertension
treatment
menopause
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60330888T
Other languages
English (en)
Inventor
Siegried Meyerhofer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/287,780 external-priority patent/US20040087563A1/en
Priority claimed from PCT/IB2002/004628 external-priority patent/WO2004041288A1/en
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Application granted granted Critical
Publication of DE60330888D1 publication Critical patent/DE60330888D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
DE60330888T 2002-11-05 2003-11-05 Verwendung von drospirenon zur behandlung von hypertension Expired - Lifetime DE60330888D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/287,780 US20040087563A1 (en) 2002-11-05 2002-11-05 Hormone replacement therapy with cardiovascular protection using antialdosteronic progestins
PCT/IB2002/004628 WO2004041288A1 (en) 2002-11-05 2002-11-05 Hormone replacement therapy with drospirenone
PCT/IB2003/004946 WO2004041289A1 (en) 2002-11-05 2003-11-05 Cardiovascular protection using anti-aldosteronic progestins

Publications (1)

Publication Number Publication Date
DE60330888D1 true DE60330888D1 (de) 2010-02-25

Family

ID=32314003

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60330888T Expired - Lifetime DE60330888D1 (de) 2002-11-05 2003-11-05 Verwendung von drospirenon zur behandlung von hypertension

Country Status (9)

Country Link
EP (1) EP1558265B1 (de)
JP (1) JP2006508945A (de)
AT (1) ATE454155T1 (de)
AU (1) AU2003278434A1 (de)
DE (1) DE60330888D1 (de)
DK (1) DK1558265T3 (de)
ES (1) ES2338781T3 (de)
PT (1) PT1558265E (de)
WO (1) WO2004041289A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1748756T3 (pl) 2004-03-10 2009-10-30 Bayer Schering Pharma Ag Kompozycje zawierające molekularnie zdyspergowany drospirenon
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
ATE469650T1 (de) * 2004-12-01 2010-06-15 Par Pharmaceuticals Inc Verwendung von megestrolacetat zur verbesserung der herzfunktion und zur behandlung von herzinsuffizienz
US20070275941A1 (en) * 2006-05-17 2007-11-29 Vladimir Hanes Salt sensitivity and prevention of hypertension with drospirenone
EP2052724A1 (de) * 2007-10-26 2009-04-29 sanofi-aventis Verwendung von Norgestimat als selektivem Hemmer der Ionenkanäle TRPC3, TRPC6 sowie TRPC6 und TRPC7
EP2383279A1 (de) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Herstellungsverfahren für Esterol
LT3310346T (lt) 2015-06-18 2021-06-10 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
SI3310345T1 (sl) 2015-06-18 2021-05-31 Estetra Sprl Orodisperzibilna tableta, ki vsebuje estetrol
PL3310333T3 (pl) 2015-06-18 2020-07-13 Estetra Sprl Ulegająca rozpadowi w jamie ustnej jednostka dawkowana zawierająca składnik estetrolowy
CN107771075A (zh) 2015-06-18 2018-03-06 密特拉制药公司 含雌四醇组分的口腔分散剂量单位
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
CN117180214A (zh) * 2023-10-26 2023-12-08 杭州和泽坤元药业有限公司 一种地屈孕酮片剂组合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
JP2003513913A (ja) * 1999-11-09 2003-04-15 ファルマシア コーポレイション 血管傷害に起因する病的変化をアルドステロンアンタゴニストで治療、阻害または予防する方法
WO2001052857A1 (en) * 2000-01-18 2001-07-26 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
AU1604001A (en) * 2000-06-13 2001-12-24 Pharmacia Corp Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
WO2002009683A2 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Aldosterone blocker therapy to prevent or treat inflammation-related disorders
ES2251505T3 (es) * 2000-08-28 2006-05-01 Pharmacia Corporation Uso de un antagonista del receptor de aldosterona para mejorar la funcion cognoscitiva.
DE10100911A1 (de) * 2001-01-11 2002-08-01 Schering Ag Verfahren zur Hormonersatztherapie und dessen Darreichungsform

Also Published As

Publication number Publication date
DK1558265T3 (da) 2010-03-15
ES2338781T3 (es) 2010-05-12
EP1558265B1 (de) 2010-01-06
EP1558265A1 (de) 2005-08-03
AU2003278434A1 (en) 2004-06-07
PT1558265E (pt) 2010-03-22
WO2004041289A1 (en) 2004-05-21
JP2006508945A (ja) 2006-03-16
ATE454155T1 (de) 2010-01-15

Similar Documents

Publication Publication Date Title
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
DE60330888D1 (de) Verwendung von drospirenon zur behandlung von hypertension
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
ATE309802T1 (de) Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungen
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
TR200002784T2 (tr) Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar
DE60315964D1 (de) Verbesserung der herstellung von endogenen gonadotropin
DE60128540D1 (de) Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen
ATE230994T1 (de) Methode zur behandlung androgenbedingter krankheiten
ATE414556T1 (de) Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
ATE500855T1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
ATE390928T1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
ATE515253T1 (de) Zusammensetzungen auf basis von etyllinoleat und triethylcitrat zur behandlung von seborrhöe und akne
DE60320770D1 (de) Verfahren zur verabreichung von buprenorphin zur behandlung von depression
ATE385807T1 (de) Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin entzug
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
ATE516366T1 (de) Regulierte aptamer-therapeutika
DE60140960D1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
ATE541565T1 (de) Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
DE69902520D1 (de) Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
ATE380558T1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
TW200501934A (en) Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set
HUP9901505A2 (hu) Dehidroepiandroszteron és aromatázgátlók kombinációja és e kombináció felhasználása férfiak relatív és abszolút androgénhiányának kezelésére szolgáló gyógyszerkészítmények előállítására

Legal Events

Date Code Title Description
8364 No opposition during term of opposition